- Taking a GLP-1 Medication? Here’s Tips to Holiday Eating
- Bird Flu Virus in Canadian Teen Shows Mutations That Could Help It Spread Among Humans
- Flu, COVID Vaccination Rates Remain Low as Winter Nears
- ’10 Americas:’ Health Disparities Mean Life Expectancy Varies Across U.S.
- Short-Term Hormone Therapy for Menopause Won’t Harm Women’s Brains
- Could a Vitamin Be Effective Treatment for COPD?
- Woman Receives World’s First Robotic Double-Lung Transplant
- Flavored Vapes Behind Big Surge in U.S. E-Cigarette Sales
- Reading Beyond Headline Rare For Most on Social Media, Study Finds
- Meds Like Ozempic Are Causing Folks to Waste More Food
Blood Test for Yeast Infections Approved
The first blood test to detect five strains of yeast that cause rare blood infections in people with weakened immune systems has been approved by the U.S. Food and Drug Administration.
The five types of yeast pathogen detected by the T2Candida test can cause deadly bloodstream infections if not treated quickly, the FDA said in a news release. People at greatest risk of the infections include those being treated for cancer, those who have been given immune system-suppressing drugs after an organ transplant and severely ill people in intensive care.
Results from the new test are available in three to five hours, compared to six days or longer from traditional methods, the FDA said. The faster results may allow doctors to begin treatment sooner.
But since false positives are possible from the new test, results should be confirmed by blood culture, the agency advised.
The new test was evaluated in clinical studies of about 1,800 people. Negative results were correctly identified nearly 100 percent of the time, and the yeast organism involved was correctly identified in 84 percent to 96 percent of positive specimens, the FDA said.
The T2Candida test is produced by T2 Biosystems, based in Lexington, Mass.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.